Transcatheter Structural Heart Disease Interventions: Clinical Update

Dear Colleagues,

Transcatheter structural heart disease interventions represent a new branch of percutaneous treatments, covering a wide range of previously surgically treated or even not addressed cardiac diseases.

Gradually, we are experiencing a technological revolution in structural heart disease management, with several new or improved devices specially dedicated to this field. We now have the tools and the impulse to go beyond previous boundaries, treating conditions considered “forgotten” for decades. Additionally, we can offer a less invasive, less morbid, safer, but still effective treatment to some of the most frequent heart diseases, such as aortic stenosis, mitral regurgitation, tricuspid regurgitation, and atrial or ventricular septum defects. Once distant on the horizon, these procedures are now part of our daily routine in CAT labs and hybrid rooms. This revolution was only possible thanks to the innovative impetus and bravery of professionals from several specialties such as cardiology, cardiac surgery, interventional cardiology, electrophysiology, imaging, heart failure, and many others.

Despite all these advancements, however, many questions remain without answer. What is the best time to intervene in primary tricuspid regurgitation? What is the long-term durability of transcatheter valves? What is the impact of subclinical leaflet thrombosis? What is the role of cerebral embolic protection devices? Should transcatheter mitral valve repair be offered to patients who are not inoperable or high-risk? Transcatheter mitral valve replacement devices should replace repair devices? When should we close iatrogenic interatrial septum defects? What is the role of intracardiac echocardiography or fusion imaging? And so on.

With this Special Issue, we aim to present the up-to-date status of Transcatheter Structural Heart Disease Interventions. We would like to invite researchers from all transcatheter structural intervention associated areas to submit original articles or reviews, sharing their expertise and knowledge on this appealing subject. 

Dr. Maurizio Taramasso
Dr. Ana Paula Tagliari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.